Clinical Characteristics of Patients With Statin Discontinuation in Korea: A Nationwide Population-Based Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveTo investigate the clinical characteristics of patients with statin discontinuation in Korea, using a nationwide database. MethodsWe analyzed 1,308,390 patients treated with statin for the first time in their life between 2016 and 2017 using the Korean National Health Information Database. The patients participated in the Korean National Health Screening Program within two years before taking statin. Patients with statin discontinuation were defined as those who were not prescribed statin between 365 days and 730 days after the initial statin prescription. ResultsThe overall prevalence of statin discontinuation was 39.44%. Patients with statin discontinuation were younger, had lower body mass index (BMI), included a higher number of smokers and drinkers, did not exercise regularly, with fewer cases of hypertension and diabetes mellitus than those without statin discontinuation (p<0.001). Compared with patients aged 20–29 years, the risk of statin discontinuation showed a U-shaped relationship with age (odds ratios [ORs]: 0.619 in 30–39 years; 0.454 in 40–49 years; 0.345 in 50–59 years; 0.307 in 60–69 years; 0.324 in 70–79 years; and 0.415 in ≥80 years). In addition, increased BMI was associated with decreased risk of statin discontinuation (ORs: 0.969 with 25.0–29.9 kg/m2, and 0.890 with ≥30.0 kg/m2). Patients with hypertension and diabetes mellitus were at a lower risk of statin discontinuation (OR: 0.414 for hypertension; 0.416 for diabetes mellitus). ConclusionThe prevalence of patients with statin discontinuation in Korea was 39.44% at 1 to 2 years after initial statin treatment.
Abstract
ObjectiveTo investigate the clinical characteristics of patients with statin discontinuation in Korea, using a nationwide database. MethodsWe analyzed 1,308,390 patients treated with statin for the first time in their life between 2016 and 2017 using the Korean National Health Information Database. The patients participated in the Korean National Health Screening Program within two years before taking statin. Patients with statin discontinuation were defined as those who were not prescribed statin between 365 days and 730 days after the initial statin prescription. ResultsThe overall prevalence of statin discontinuation was 39.44%. Patients with statin discontinuation were younger, had lower body mass index (BMI), included a higher number of smokers and drinkers, did not exercise regularly, with fewer cases of hypertension and diabetes mellitus than those without statin discontinuation (p<0.001). Compared with patients aged 20–29 years, the risk of statin discontinuation showed a U-shaped relationship with age (odds ratios [ORs]: 0.619 in 30–39 years; 0.454 in 40–49 years; 0.345 in 50–59 years; 0.307 in 60–69 years; 0.324 in 70–79 years; and 0.415 in ≥80 years). In addition, increased BMI was associated with decreased risk of statin discontinuation (ORs: 0.969 with 25.0–29.9 kg/m2, and 0.890 with ≥30.0 kg/m2). Patients with hypertension and diabetes mellitus were at a lower risk of statin discontinuation (OR: 0.414 for hypertension; 0.416 for diabetes mellitus). ConclusionThe prevalence of patients with statin discontinuation in Korea was 39.44% at 1 to 2 years after initial statin treatment.
참고문헌 (40)
- Kim KS, "Assessing the validity of the criteria for the extreme risk category of atherosclerotic cardiovascular disease : a nationwide population-based study", J Lipid Atheroscler, 11, pp.73~83 (2022)
- Kim KS, "Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels", Metabolism, 137, pp.155327~ (2022)
- Taylor F, "Statins for the primary prevention of cardiovascular disease", Cochrane Database Syst Rev, 2013, pp.CD004816~ (2013)
- Fulcher J, "Efficacy and safety of LDL-lowering therapy among men and women : meta-analysis of individual data from 174, 000 participants in 27 randomised trials", Lancet, 385, pp.1397~1405 (2015)
- Jeong H, "Low-density lipoprotein cholesterol level, statin use and myocardial infarction risk in young adults", J Lipid Atheroscler, 11, pp.288~298 (2022)
- Trusler D, "Statin prescriptions in UK now total a million each week", BMJ, 343, pp.d4350~ (2011)
- Mihaylova B, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease : meta-analysis of individual data from 27 randomised trials", Lancet, 380, pp.581~590 (2012)
- Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
- Ellis JJ, "Suboptimal statin adherence and discontinuation in primary and secondary prevention populations", J Gen Intern Med, 19, pp.638~645 (2004)
- Davidson MH, "Safety of aggressive lipid management", J Am Coll Cardiol, 49, pp.1753~1762 (2007)
- Holme I, "Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study", Eur J Cardiovasc Prev Rehabil, 16, pp.315~320 (2009)
- Zhang H, "Discontinuation of statins in routine care settings : a cohort study", Ann Intern Med, 158, pp.526~534 (2013)
- Svensson E, "Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care : a Danish population-based study", Clin Epidemiol, 7, pp.213~223 (2015)
- Ho PM, "Medication adherence : its importance in cardiovascular outcomes", Circulation, 119, pp.3028~3035 (2009)
- Martin-Ruiz E, "Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention", J Cardiovasc Pharmacol Ther, 23, pp.200~215 (2018)
- Pittman DG, "Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations", Am J Cardiol, 107, pp.1662~1666 (2011)
- Cutler RL, "Economic impact of medication non-adherence by disease groups : a systematic review", BMJ Open, 8, pp.e016982~ (2018)
- Mann DM, "Predictors of nonadherence to statins : a systematic review and meta-analysis", Ann Pharmacother, 44, pp.1410~1421 (2010)
- Pfeffer MA, "Safety and tolerability of pravastatin in long-term clinical trials : prospective Pravastatin Pooling(PPP)Project", Circulation, 105, pp.2341~2346 (2002)
- Silva M, "Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy", Clin Ther, 29, pp.253~260 (2007)
- Yang YS, "Lipid management in Korean people with type 2 diabetes mellitus : Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis consensus statement", Diabetes Metab J, 47, pp.1~9 (2023)
- Donnelly LA, "Long-term adherence to statin treatment in diabetes", Diabet Med, 25, pp.850~855 (2008)
- Yang CC, "Discontinuation and switching of therapy after initiation of lipid-lowering drugs : the effects of comorbidities and patient characteristics", Br J Clin Pharmacol, 56, pp.84~91 (2003)
- Perreault S, "Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease", Eur J Clin Pharmacol, 61, pp.667~674 (2005)
- Glader EL, "Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke", Stroke, 41, pp.397~401 (2010)
- Shah ND, "Long-term medication adherence after myocardial infarction : experience of a community", Am J Med, 122, pp.961~ (2009)
- Haam JH, "Diagnosis of obesity : 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity", J Obes Metab Syndr, 32, pp.121~129 (2023)
- Brown MT, "Medication adherence : WHO cares?", Mayo Clin Proc, 86, pp.304~314 (2011)
- Lemstra M, "Proportion and risk indicators of nonadherence to statin therapy : a meta-analysis", Can J Cardiol, 28, pp.574~580 (2012)
- Benner JS, "Long-term persistence in use of statin therapy in elderly patients", JAMA, 288, pp.455~461 (2002)
- Ofori-Asenso R, "Predictors of first-year nonadherence and discontinuation of statins among older adults : a retrospective cohort study", Br J Clin Pharmacol, 85, pp.227~235 (2019)
- Vinogradova Y, "Discontinuation and restarting in patients on statin treatment : prospective open cohort study using a primary care database", BMJ, 353, pp.i3305~ (2016)
- Benner JS, "Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy", Pharmacoeconomics, 22(Suppl 3), pp.13~23 (2004)
- Schneeweiss S, "Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction : a population-based natural experiment", Circulation, 115, pp.2128~2135 (2007)
- Halava H, "Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities", CMAJ, 186, pp.E449~ (2014)
- Kopjar B, "Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population", Am J Cardiol, 92, pp.1106~1108 (2003)
- Kamal-Bahl SJ, "Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice", Am J Cardiol, 99, pp.530~534 (2007)
- Sigglekow F, "Statin adherence is lower in primary than secondary prevention : a national follow-up study of new users", PLoS One, 15, pp.e0242424~ (2020)